World Health Organization Sounds Concern Over Critical Scarcity of Weight-Loss Injections

Under 10% of people that would benefit from obesity jabs such as Wegovy are able to get them, states the global health agency as it releases its first advice on the therapies.

Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.

Based on projections, over two billion will be obese by 2030 if no action is taken.

"The latest guidelines affirms that obesity is a lifelong illness that can be addressed with comprehensive and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and distribution challenges are key barriers to broad access to the injections that can assist patients in reducing significant body mass, explains the organization.

Weight-Loss Drug Scarcity

Despite the present most optimistic scenario, the supply of GLP-1 therapies would only suffice for around 100 million people – less than 10% of eligible patients, as stated by the WHO.

The recommendation calls on nations and manufacturers to expand availability, via measures including patent sharing.

The intellectual property rights on the active ingredient – the primary component of a leading brand – is scheduled to end in a number of countries in 2026.

How Obesity Injections Function

The injections mimick a biological compound to slow digestion, suppress the appetite and increase satiety so people eat less.

People usually begin shedding pounds after several weeks of beginning the regular doses.

Research indicates users may see weight return a year later of halting the medication, because their usual food cravings come back.

To be above a healthy weight elevates your chance for contracting diseases, including diabetes, cardiovascular issues, brain attack, and specific malignancies.

Obesity concerns individuals in every country and was associated with 3.7 million deaths worldwide in 2024, as per the health agency.